替诺福韦1%阴道凝胶预防南非女性HIV-1感染的FACTS-001三期试验
FACTS-001是在南非9个社区临床试验点开展的3期随机双盲安慰剂对照试验,纳入2059名18-30岁HIV阴性性活跃女性,评估围性交使用替诺福韦1%凝胶的安全性和有效性。结论认为围性交替诺福韦凝胶未能预防该人群HIV-1感染。
要点
- 围性交使用替诺福韦1%凝胶未降低南非年轻女性HIV-1感染风险。
- 替诺福韦组2级不良事件发生率略高于安慰剂组,无产品相关严重不良事件。
- 需要不依赖高依从性的替代安全有效产品。
核心结论
- 围性交使用替诺福韦1%凝胶未能预防南非HIV感染风险年轻女性的HIV-1感染。
研究设计与样本
- 3期随机双盲安慰剂对照试验在南非9个社区临床试验点开展,筛查3844人,入组2059名18-30岁HIV阴性性活跃女性,按1:1随机分配至替诺福韦1%凝胶或安慰剂凝胶。
- 主要分析纳入2029人(替诺福韦组1032人,安慰剂组1027人),随访至27个月,每月检测HIV-1。
主要发现
- 最常见2级及以上产品相关不良事件为低磷血症(替诺福韦组22例 vs 安慰剂组22例)、生殖器症状(6例 vs 2例)和转氨酶升高(2例 vs 2例)。
关键数值与推荐
- 主要疗效终点为HIV-1新发感染,主要安全性终点为2-4级不良事件,均在改良意向治疗人群中分析。
临床怎么用
- 不推荐将围性交替诺福韦1%凝胶用于南非年轻女性的HIV预防。
- 需寻找不依赖高依从性的替代安全有效预防产品。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Young women in southern Africa have substantial risk of HIV acquisition. Female-controlled biomedical interventions are needed to mitigate this risk. We aimed to assess the safety and efficacy of a pericoitally applied tenofovir 1% gel. METHODS: We did a phase 3, double-blind, randomised, placebo-controlled trial at nine community-based clinical trial sites in South Africa to evaluate the safety and efficacy of tenofovir 1% gel. Sexually active women who were HIV negative and aged 18-30 years were enrolled. Participants were randomly assigned (1:1) using sequential participant numbers to either tenofovir 1% gel or a placebo gel (one dose within 12 h before sex and one dose within 12 h after sex [BAT-24 regimen]), using dynamic permuted block sizes of 8 and 16 within each site. Women received monthly HIV-1 testing, risk reduction support, physical examinations, and product dispensing for up to 27 months. The primary efficacy outcome was incident HIV infection and the primary safety outcome was occurrence of grade 2-4 adverse events, both analysed in the modified intention-to-treat population. To assess the efficacy of tenofovir gel, the cumulative probability of HIV infection was calculated for each treatment using the Kaplan-Meier method. This trial is registered with ClinicalTrials.gov, number NCT01386294. FINDINGS: From Oct 11, 2011, to Aug 29, 2014, 3844 women were screened, 2059 enrolled, and 2029 included in the primary analysis (1032 in the tenofovir group and 1027 in the placebo group); 39 (4%) in the tenofovir group and 36 (4%) in the placebo group were lost to follow-up. 123 HIV-1 infections occurred over 3036 woman-years of observation; 61 in the tenofovir group (HIV incidence 4·0 per 100 woman-years, 95% CI 3·1-5·2) and 62 in the placebo group (4·0 per 100 woman-years, 3·1-5·2; incidence rate ratio [IRR] 0·98, 95% CI 0·7-1·4). A higher incidence of grade 2 adverse events was observed in the tenofovir group than in the placebo group (IRR 1·09, 95% CI 1·0-1·2; p=0·02). The most common grade 2 or higher product-related adverse events were hypophosphataemia (n=22 for tenofovir vs n=22 for placebo), genital symptoms (n=6 for tenofovir vs n=2 for placebo), or elevated transaminases (n=2 for tenofovir vs n=2 for placebo). No product-related serious adverse events were reported, and no differences in product-related adverse events (p=0·78), grade 3 events (p=0·64), or grade 4 events (p=0·74) were observed between treatment groups. INTERPRETATION: Overall, pericoital tenofovir gel did not prevent HIV-1 acquisition in this population of young women at risk of HIV infection in South Africa. Alternate safe and effective products that are less user dependent than this product or do not require high adherence are needed. FUNDING: The US Agency for International Development (USAID), the Bill & Melinda Gates Foundation, and the South African Department of Science and Technology and Department of Health.
引用
- Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018. PMID: 30507409. doi:10.1016/S1473-3099(18)30428-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。